Esperanza Lavilla-Rubira Selected Research

Drug Therapy (Chemotherapy)

5/2023	Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
1/2022	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
3/2020	Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Esperanza Lavilla-Rubira Research Topics

Disease

3	COVID-19 01/2024 - 01/2023
3	Neoplasms (Cancer) 10/2023 - 03/2020
2	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 01/2023
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2023 - 01/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022
1	Leukemia 01/2021

Drug/Important Bio-Agent (IBA)

1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2024
1	Antiviral Agents (Antivirals)IBA 10/2023
1	molnupiravirIBA 10/2023
1	nirmatrelvir and ritonavir drug combinationIBA 10/2023
1	tixagevimabIBA 01/2023
1	cilgavimabIBA 01/2023

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 05/2023 - 03/2020
1	Radiotherapy 01/2022
1	Therapeutics 01/2022
1	Stem Cell Transplantation 01/2021
1	Transplantation 01/2021